|
Mar 14
|
Seres Therapeutics, Inc. (NASDAQ:MCRB): Are Analysts Optimistic?
|
|
Mar 14
|
Seres Therapeutics Inc (MCRB) Q4 2024 Earnings Call Highlights: Financial Improvements and ...
|
|
Mar 14
|
Q4 2024 Seres Therapeutics Inc Earnings Call
|
|
Mar 13
|
Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
|
|
Mar 3
|
Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach
|
|
Oct 8
|
Institutions along with retail investors who hold considerable shares inSeres Therapeutics, Inc. (NASDAQ:MCRB) come under pressure; lose 12% of holdings value
|
|
Sep 30
|
Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A
|
|
Sep 26
|
Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30
|
|
May 13
|
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Seres Therapeutics First Quarter 2024 Earnings: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023)
|
|
May 9
|
Seres Therapeutics Inc (MCRB) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...
|
|
May 8
|
Seres Therapeutics Reports Q1 2024 Earnings: Surpasses Revenue Estimates
|
|
May 8
|
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
|
|
May 6
|
Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
|
|
Apr 9
|
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
|
|
Mar 28
|
Increases to Seres Therapeutics, Inc.'s (NASDAQ:MCRB) CEO Compensation Might Cool off for now
|
|
Mar 19
|
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 13
|
11 Oversold NASDAQ Stocks To Buy Right Now
|
|
Mar 13
|
11 Oversold Healthcare Stocks To Buy Right Now
|
|
Mar 7
|
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2023 Earnings Call Transcript
|